Lv7
5010 积分 2021-06-27 加入
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
8天前
已完结
Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response?
8天前
已关闭
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
1个月前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
1个月前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
1个月前
已完结
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
1个月前
已完结
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care
2个月前
已关闭
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
2个月前
已完结
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care
2个月前
已关闭
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
2个月前
已完结
皖公网安备34019202002308
